$268 Billion in U.S. Life Science Investment in 2025
America leads the world in healthcare innovation and access, and a strong medical infrastructure is essential to maintain this standing for our national security.
This year, the life sciences sector has delivered.
We Work For Health is tracking every new U.S. biopharma facility announcement and news report, revealing more than $268 billion invested to drive new R&D, expand manufacturing and create jobs nationwide.
Investment in America
These investments bring cutting edge treatments closer to the patients who need them while bolstering America’s position as a world leader in healthcare access and innovation. The positive impact of these investments reaches deep into U.S. communities, with millions of high-skill positions for scientists and engineers, alongside tens of thousands of construction and support roles and millions of jobs for the communities surrounding these cutting edge faciltiies. This includes more than 4.9 million total U.S. jobs and $71.6 billion in vendor spending in states along with $2.6B in wages paid to the American construction workforce.
766%
increase in facility investment announcements versus 2024
10K+
new construction jobs across America
The biopharmaceutical industry’s investments reflect a commitment to ensuring the U.S. remains a leader in the life sciences, but China continues a coordinated campaign to dominate the life sciences, jeopardizing America’s momentum.
It’s essential to have the right policies in place that encourage continued investment to secure America’s future as the global leader in life sciences.
Faster delivery
of breakthrough medicines to patients
U.S. Life Sciences Investment Tracker:
February 23, 2026
AbbVie
$380 million
North Chicago-IL
Two new active pharmaceutical ingredient (API) manufacturing facilities that will integrate advanced manufacturing technologies with artificial intelligence to support the production of next-generation neuroscience and obesity medications. To support these new facilities, AbbVie will hire 300 people in North Chicago, including engineers, scientists, manufacturing operators and lab technicians.
Part of a larger, previously announced $100 billion company investment.
February 18, 2026
Johnson & Johnson
$1 billion
Lower Gwynedd-PA
New next-generation cell therapy manufacturing facility that will support 500 skilled biomanufacturing jobs and more than 4,000 construction jobs during the site's development. Expanded details for a project first announced in January 2026.
Part of a larger, previously announced $55 billion company investment.
January 30, 2026
Eli Lilly
$3.5 billion
Fogelsville-PA
A new injectable medicine and device manufacturing facility that will produce next-generation weight-loss therapies. The project will bring 850 high-value jobs to the Lehigh Valley area, including engineers, scientists, operations personnel and lab technicians.
Part of a larger, previously announced $27 billion company investment.
January 20, 2026
Roche
$1.3 billion
Holly Springs-NC
An expansion of Genentech’s (Roche’s U.S. subsidiary) initial $700 million investment in a new fill-finish biologics plant, bringing the total investment in this facility to $2 billion.
The expanded investment will include additional production capacity and support an additional 100 new jobs once completed.
Part of a larger, previously announced $50 billion company investment.
January 12, 2026
AbbVie
$90 billion
Unspecified location
Pledging an additional $90 billion toward U.S.-based research and development and capital investments, including manufacturing, over the next decade to bring the company’s total commitment to $100 billion.
AbbVie previously committed to a $10 billion U.S. expansion in April 2025.
January 9, 2026
Novartis
Unspecified
Winter Park-FL
A new radioligand therapy (RLT) manufacturing site is expected to come online by 2029 and strengthen the company’s specialized supply chain and manufacturing capabilities across its network of RLT production facilities.
Part of a larger, previously announced $23 billion company investment.
December 9, 2025
Eli Lilly
$6 billion
Huntsville-AL
A new, next-generation active pharmaceutical ingredient (API) facility that will support the production of small molecule synthetic and peptide medicines, including an oral GLP-1. The project will bring “450 high-value jobs” to the area, including engineers, scientists, operations personnel and lab technicians, and 3,000 construction jobs.
Part of a larger, previously announced $27 billion company investment.
November 21, 2025
AstraZeneca
$2 billion
Frederick-MD, Gaithersburg-MD
Expansion of the company’s flagship biologics manufacturing facility in Frederick and the construction of a new state-of-the-art facility in Gaithersburg for the development of innovative molecules to be used in clinical trials.
The investment will support 2,600 jobs across the two sites, including the retention of local jobs, construction activity, and the creation of 300 highly skilled jobs.
Part of a larger, previously announced $50 billion company investment.
No entries found matching your criteria. Please modify your filters.